The global drug formulation market size is estimated at USD 1.85 trillion in 2024, grew to USD 1.96 trillion in 2025 and is predicted to surpass around USD 3.32 trillion by 2034, expanding at a CAGR of 6.05% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Drug Formulation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Drug Formulation Market, by Formulation, 2024-2034
8.1.1. Tablets
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Capsules
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Injectable
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Sprays
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Suspensions
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Powders
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Other Formulations
8.1.7.1. Market Revenue and Forecast (2021-2034)
9.1. Drug Formulation Market, by Routes of Administration, 2024-2034
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Topical
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Parenteral
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Inhalations
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Other Routes of Administration
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Drug Formulation Market, by Therapy Area, 2024-2034
10.1.1. Cardiovascular Diseases (CVDs)
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Pain
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Diabetes
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Cancer
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Respiratory Diseases
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Other Diseases
10.1.6.1. Market Revenue and Forecast (2021-2034)
11.1. Drug Formulation Market, by End-User, 2024-2034
11.1.1. Retail
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Non-retail
11.1.2.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.1.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.1.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.1.4. Market Revenue and Forecast, by End-User (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.2.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.2.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.3.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.3.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.4.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.4.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.5.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.5.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Formulation (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Routes of Administration (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Therapy Area (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End-User (2021-2034)
13.1. Bristol-Myers Squibb
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eli Lilly and Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Gilead Sciences, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Merck & Co., Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Novartis AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AbbVie Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Boehringer Ingelheim International GmbH
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. F. Hoffmann-La Roche AG
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample